Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense? HER2 Imaging Agent

Imagion Biosystems Limited (ASX: IBX) recently announced positive results following completion of the IBI10103 phase I clinical trial evaluating the safety and clinical feasibility of MagSense? HER2 Imaging Agent (MSH2IA) as an adjunct to MRI for the assessment of axillary lymph node metastasis in patients diagnosed with HER2+ primary breast cancer. The trial met its endpoint of safety and tolerability, and showed that blinded radiologists may be able to distinguish suspicious lymph nodes that a